Somatic state assessment of the health of patients with retinoblastoma in a long-term follow-up

Abstract

AIM: To comprehensively assess the incidence and nature of the chronic diseases in patients with retinoblastoma in the long-term follow-up

MATERIAL AND METHODS: The study analyzed the long-term treatment results of 176 patients with retinoblastoma. Group 1 included 46 patients aged <18 years and Group 2 included 88 patients aged >18 and <35 years. A gynecologist and a urologist were consulted, a medical history was taken, and a physical examination with emphasis on the presence of secondary sexual characteristics and laboratory tests were performed to assess the endocrine function in surviving patients aged <18 years. Anamnestic data were used in patients aged >18 years.

RESULTS: The somatic status data analysis of 46 surviving adolescents revealed that 29 (63%) have abnormalities. Chronic gastritis and gastroduodenitis, biliary dyskinesia, fatty hepatosis, and lactase deficiency predominate in gastrointestinal structure diseases. Respiratory diseases are represented by chronic nasopharyngeal diseases in 13.0% of children. Secondary immunodeficiency condition was diagnosed in 3 (6.5%) patients. Musculoskeletal system and connective tissue pathologies in deforming dorsopathies were identified in 10.9% of cases and bone and joint pain were identified in 8.7%. Chronic conditions were found in 42 (47.7%) of 88 patients in Group 2. Somatic disorders were found in 95.2%, hormonal disorders in 11.9%, psycho-emotional disorders in 9.5%, and combined pathology in 9.5% of cases. Endocrine pathology was detected in 14 patients (30.4%) aged <18 years.

CONCLUSION: Retinoblastoma survivors have a high risk of somatic and endocrine disorders. The main risk factors are distance radiation therapy and alkylating agents. Regular lifelong follow-up of these patients is necessary to establish a medical rehabilitation system for children with retinoblastoma.

Keywords

retinoblastoma / chemotherapy / radiation therapy / somatic disorders / endocrine complications

References

[1] Saakjan SV, Tadevosjan SS, Cygankov AJ. Analysis of retinoblastoma incidence in children. Rossijskaja pediatricheskaja oftal’mologija. 2020; 15(4): 5–10. (In Russ). doi: 10.17816/rpo2020-15-4-5-10

[2] Саакян С.В., Тадевосян С.С., Цыганков А.Ю. Анализ структуры заболеваемости ретинобластомой у детей. Российская педиатрическая офтальмология. 2020. Т. 15, № 4. С. 5–10. doi: 10.17816/rpo2020-15-4-5-10

[3] Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009;27(14):2339–2355. doi: 10.1200/JCO.2008.21.1953

[4] Diller L., Chow E.J., Gurney J.G., et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings // J Clin Oncol. 2009. Vol. 27, N 14. P. 2339–2355. doi: 10.1200/JCO.2008.21.1953

[5] Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–2715. doi: 10.1001/jama.297.24.2705

[6] Geenen M.M., Cardous-Ubbink M.C., Kremer L.C., et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer // JAMA. 2007. Vol. 297, N 24. P. 2705–2715. doi: 10.1001/jama.297.24.2705

[7] Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–2381. doi: 10.1001/jama.2013.6296

[8] Hudson M.M., Ness K.K., Gurney J.G., et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer // JAMA. 2013. Vol. 309, N 22. P. 2371–2381. doi: 10.1001/jama.2013.6296

[9] Hudson MM, Mulrooney DA, Bowers DC, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol. 2009;27(14):2405–2414. doi: 10.1200/JCO.2008.21.1516

[10] Hudson M.M., Mulrooney D.A., Bowers D.C., et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance // J Clin Oncol. 2009. Vol. 27, N 14. P. 2405–2414. doi: 10.1200/JCO.2008.21.1516

[11] Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368–1379. doi: 10.1093/jnci/djn310

[12] Mertens A.C., Liu Q., Neglia J.P., et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study // J Natl Cancer Inst. 2008. Vol. 100, N 19. P. 1368–1379. doi: 10.1093/jnci/djn310

[13] Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582. doi: 10.1056/NEJMsa060185

[14] Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer // N Engl J Med. 2006. Vol. 355, N 15. P. 1572–1582. doi: 10.1056/NEJMsa060185

[15] Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38(4):229–239. doi: 10.1002/mpo.1316

[16] Robison L.L., Mertens A.C., Boice J.D., et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project // Med Pediatr Oncol. 2002. Vol. 38, N 4. P. 229–239. doi: 10.1002/mpo.1316

[17] Tkachenko IV, Teslenko BV, Rogacheva ER, et al. Health status of children treated for oncohematological diseases. Voprosy prakticheskoj pediatrii. 2009; 4(5): 22–27 (In Russ).

[18] Ткаченко И.В., Тесленко Б.В., Рогачева Е.Р., и др. Состояние здоровья детей, излеченных от онкогематологических заболеваний // Вопросы практической педиатрии. 2009. Т. 4, № 5. С. 22–27.

[19] Radulesku GG, Matchenkova NV, Belogurova MB. The endocrinological complications in children after anticancer treatment. Pediatr. 2016;7(1):120–128. (In Russ). doi: 10.17816/PED71120-128

[20] Радулеску Г.Г., Матченкова Н.В., Белогурова М.Б. Эндокринологические осложнения у пациентов, получивших противоопухолевую терапию в детском возрастe // Педиатр. 2016. Т. 7, № 1. С. 120–128. doi: 10.17816/PED71120-128

[21] Petrushkina AA, Pigarova EA, Rozhinskaja LY. The prevalence of vitamin D deficiency in Russian Federation. Osteoporoz i osteopatii. 2018;21(3):15–20. (In Russ). doi: 10.14341/osteo10038

[22] Петрушкина А.А., Пигарова Е.А., Рожинская Л.Я. Эпидемиология дефицита витамина D в Российской Федерации // Остеопороз и остеопатии. 2018. Т. 21, № 3. С. 15–20. doi: 10.14341/osteo10038

[23] Burluckaja AV, Shadrin SA, Statova AV. Endocrine pathology in adolescents in Krasnodar. Mezhdunarodnyj nauchno-issledovatel’skij zhurnal. 2016;11(53):130–134. (In Russ). doi: 10.18454/IRJ.2016.53.197

[24] Бурлуцкая А.В., Шадрин С.А., Статова А.В. Эндокринная патология у подростков города Краснодара // Международный научно-исследовательский журнал. 2016. № 11. С. 130–134. doi: 10.18454/IRJ.2016.53.197

[25] Friedman DN, Chou JF, Oeffinger KC, et al. Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. Cancer. 2016;122(5):773–781. doi: 10.1002/cncr.29704

[26] Friedman D.N., Chou J.F., Oeffinger K.C., et al. Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study // Cancer. 2016. Vol. 122, N 5. P. 773–781. doi: 10.1002/cncr.29704

[27] Seth R, Singh A, Guru V, et al. Long-term follow-up of retinoblastoma survivors: Experience from India. South Asian J Cancer. 2017;6(4):176–179. doi: 10.4103/sajc.sajc_179_16

[28] Seth R., Singh A., Guru V., et al. Long-term follow-up of retinoblastoma survivors: Experience from India // South Asian J Cancer. 2017. Vol. 6, N 4. P. 176–179. doi: 10.4103/sajc.sajc_179_16

[29] Schundeln MM, Hauffa PK, Bauer JJ, et al. Pediatric Survivors of Retinoblastoma Are at Risk for Altered Bone Metabolism After Chemotherapy Treatment Early in Life. Pediatr Hematol Oncol. 2015;32(7):455–466. doi: 10.3109/08880018.2015.1048912

[30] Schundeln M.M., Hauffa P.K., Bauer J.J., et al. Pediatric Survivors of Retinoblastoma Are at Risk for Altered Bone Metabolism After Chemotherapy Treatment Early in Life // Pediatr Hematol Oncol. 2015. Vol. 32, N 7. P. 455–466. doi: 10.3109/08880018.2015.1048912

[31] Peylan-Ramu N, Bin-Nun A, Skleir-Levy M, et al. Orbital growth retardation in retinoblastoma survivors: work in progress. Med Pediatr Oncol. 2001;37(5):465–470. doi: 10.1002/mpo.1231

[32] Peylan-Ramu N., Bin-Nun A., Skleir-Levy M., et al. Orbital growth retardation in retinoblastoma survivors: work in progress // Med Pediatr Oncol. 2001. Vol. 37, N 5. P. 465–470. doi: 10.1002/mpo.1231

[33] Nahum MP, Gdal-On M, Kuten A, et al. Long-term follow-up of children with retinoblastoma. Pediatr Hematol Oncol. 2001;18(3):173–179. doi: 10.1080/08880010151114769

[34] Nahum M.P., Gdal-On M., Kuten A., et al. Long-term follow-up of children with retinoblastoma // Pediatr Hematol Oncol. 2001. Vol. 18, N 3. P. 173–179. doi: 10.1080/08880010151114769

RIGHTS & PERMISSIONS

Eco-Vector